Press release
Checkpoint Inhibitors Clinical Trials Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight
Checkpoint Inhibitors Clinical Trials
DelveInsight's 'Checkpoint Inhibitors Competitive Landscape 2024' report provides comprehensive global coverage of available, marketed, and pipeline checkpoint inhibitor drugs in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the checkpoint inhibitors competitive domain.
Request for free sample page @ Checkpoint Inhibitors Pipeline Analysis - https://www.delveinsight.com/report-store/checkpoint-inhibitors-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr
Some facts of the Checkpoint Inhibitors Pipeline Competitive Landscape Report
• Over 180+ checkpoint inhibitors companies are evaluating 250+ checkpoint inhibitors pipeline therapies in various stages of development, and their anticipated acceptance in the checkpoint inhibitors market would significantly increase market revenue.
• Various leading companies in the field of checkpoint inhibitors, such as BeBetter Med, BIOCAD, CanBas Co., Ltd., Laekna Therapeutics, Genentech, Alphamab Oncology, Hangzhou Sumgen Biotech, Harbour BioMed, Aurigene Discovery Technologies, BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, Eucure Biopharma, PharmaEngine, Vernalis, Array BioPharma, Genentech, Boehringer Ingelheim, Sentinel Oncology, Sierra Oncology, IMPACT Therapeutics, Alpine Immune Sciences, Arcus Biosciences, Elpiscience Biopharmaceuticals, TransCode Therapeutics, Checkpoint Therapeutics, Orum Therapeutics, Avacta, Exelixis, and others, are currently examining novel candidates for checkpoint inhibitor drugs in order to enhance the treatment landscape.
• Promising checkpoint inhibitor pipeline therapies in various stages of development include BCD-100, CBP501, BEBT-260, FAZ053, Envafolimab, SG 12473, HBM-9027, CA-170, Tislelizumab, Geptanolimab, BCN 176, PH-3861, Adebrelimab, M7824, IBI-310, AGEN-1181, YH-001, PEP07, V-158411, Prexasertib, GDC-0575, PH-762, BI 765063, SOL-578, SRA 737, IMP 10, VER250840, ALPN-202, Zimberelimab, ES101, ES019, TTX siPDL1, Cosibelimab, Research programme: PD-1-Cbl-b therapeutics, APL 502, APL-801, AVA 028, AVA 021, LR-19128 PD-L1 XT, XB-628, XB014, SHR 1701 and others.
• In April 2023, Enlivex Therapeutics Ltd. announced a clinical collaboration agreement with BeiGene. The Company entered into this collaboration to evaluate the safety and efficacy of Allocetra, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for the treatment of patients with advanced-stage solid tumors, a part of the Company's ongoing Phase I/II clinical trial.
Request a sample and discover the recent advances in the checkpoint inhibitors market @ Checkpoint Inhibitors Market Dynamics - https://www.delveinsight.com/sample-request/checkpoint-inhibitors-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr
Checkpoint Inhibitors Overview
Checkpoint inhibitors are a type of immunotherapy. They obstruct proteins that prevent the immune system from attacking cancer cells. Cancer medications do not usually fit neatly into a specific form of treatment, and this is because certain medications function in multiple methods and belong to more than one class. Checkpoint inhibitors are frequently referred to as monoclonal antibodies or targeted treatments. The immune system protects humans from disease by killing germs and viruses, and t cells are the most common type of immune cell that achieves this.
Checkpoint inhibitors are drugs that suppress checkpoint proteins. They prevent proteins in cancer cells from pressing the stop button, and this activates the immune system, allowing T cells to locate and attack cancer cells. These medications inhibit the following checkpoint proteins: CTLA-4 (cytotoxic T lymphocyte-associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed cell death ligand 1). T cells express CTLA-4 and PD-1, and PD-L1 is found in cancer cells. These medications stimulate all immune cells, not just those that fight cancer. As a result, hyperactive T cells may have unintended consequences.
Find out more about FDA checkpoint inhibitors @ Checkpoint Inhibitors Clinical Trials and FDA Approvals - https://www.delveinsight.com/sample-request/checkpoint-inhibitors-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr
Checkpoint Inhibitors Pipeline Analysis: Drug Profile
BCD-100: BIOCAD
Prolgolimab (BCD-100), developed by BIOCAD, is a completely human monoclonal antibody with PD-1 receptor specificity. It is an immunoglobulin G1 with L234A/L235A mutations that result in reduced affinity for Fc receptors. It is Eastern Europe's first immune checkpoint inhibitor. In Russia, prolgolimab is already approved for the treatment of unresectable or metastatic melanoma. Prolgolimab is also being developed in combination with other medicines for the treatment of advanced NSCLC and cervical cancer as part of the Harmony clinical program. The drug is currently in Phase III development for the treatment of Non-Squamous Non-Small Cell Lung Neoplasm.
CBP501: CanBas Co., Ltd.
CanBas's CBP501 is a novel calmodulin-modulating peptide with a well-defined multimodal anti-tumor function. This mode of action leads to increased platinum influx into and cytotoxicity to tumor cells, specifically, immunogenic cell death of tumor cells, suppression of M2 macrophage activity, reduced populations of cancer stem cells, and reduced migration/invasion by and epithelial-to-mesenchymal transition (EMT) of tumor cells even with short-term exposure treatment. CBP501 also improves the efficacy of some immune checkpoint inhibitors when combined with cisplatin or carboplatin. In the CT-26 syngeneic mice model, CBP501 and a platinum drug combined with anti-PD1, anti-PDL1, or anti-CTLA4 inhibit tumor growth while increasing CD8 T cells and decreasing M2 macrophages at tumor locations. The drug is currently in a Phase II clinical trial for the treatment of Stage IV pancreatic cancer.
Checkpoint Inhibitors Pipeline Drugs:
• BCD-100: BIOCAD
• Envafolimab: 3D Medicines
• IBI310: Innovent Biologics
• Bintrafusp alfa: EMD Serono/Merck
• CA-170: Aurigene Discovery Technologies
• CBP501: CanBas Co., Ltd.
• Botensilimab: Agenus
• FAZ053: Laekna Therapeutics
• BEBT-260: BeBetter Med
• SG 12473: Hangzhou Sumgen Biotech
• HBM-9027: Harbour BioMed
• PH-3861: Phio Pharmaceuticals
Learn more about the checkpoint inhibitor drugs @ Checkpoint Inhibitors Companies - https://www.delveinsight.com/sample-request/checkpoint-inhibitors-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr
Scope of the Checkpoint Inhibitors Competitive Landscape Report
• Coverage: Global
• Key Checkpoint Inhibitors Companies: BeBetter Med, BIOCAD, CanBas Co., Ltd., Laekna Therapeutics, Genentech, Alphamab Oncology, Hangzhou Sumgen Biotech, Harbour BioMed, Aurigene Discovery Technologies, BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, Eucure Biopharma, PharmaEngine,Vernalis, Array BioPharma, Genentech, Boehringer Ingelheim, Sentinel Oncology, Sierra Oncology, IMPACT Therapeutics, Alpine Immune Sciences, Arcus Biosciences, Elpiscience Biopharmaceuticals, and others
• Key Checkpoint Inhibitors Pipeline Therapies: BCD-100, CBP501, BEBT-260, FAZ053, Envafolimab, SG 12473, HBM-9027, CA-170, Tislelizumab, Geptanolimab, BCN 176, PH-3861, Adebrelimab, M7824, IBI-310, AGEN-1181, YH-001, PEP07, V-158411, Prexasertib, GDC-0575, PH-762, BI 765063, SOL-578, SRA 737, IMP 10, VER250840, ALPN-202, Zimberelimab, ES101, ES019, and others.
• Company Analysis, Therapeutic Assessment, Pipeline Assessment, Inactive drugs assessment, Unmet Needs
Dive deep for rich insights into checkpoint inhibitor therapy; visit @ Checkpoint Inhibitors Treatment Market - https://www.delveinsight.com/sample-request/checkpoint-inhibitors-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Checkpoint Inhibitors Pipeline Report Introduction
2. Checkpoint Inhibitors Pipeline Report Executive Summary
3. Checkpoint Inhibitors Pipeline: Overview
4. Marketed Checkpoint Inhibitors Drugs
4.1. Pembrolizumab: Merck
5. Checkpoint Inhibitors Clinical Trial Therapeutics
6. Checkpoint Inhibitors Pipeline: Late-Stage Products (Pre-registration)
7. Checkpoint Inhibitors Pipeline: Late-Stage Products (Phase III)
7.1. BCD-100: BIOCAD
8. Checkpoint Inhibitors Pipeline: Mid-Stage Products (Phase II)
8.1. CBP501: CanBas Co., Ltd.
9. Checkpoint Inhibitors Pipeline: Early-Stage Products (Phase I)
9.1. BEBT-260: BeBetter Med
10. Checkpoint Inhibitors Pipeline Therapeutic Assessment
11. Inactive Products in the Checkpoint Inhibitors Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Unmet Needs
14. Checkpoint Inhibitors Market Drivers and Barriers
15. Appendix
Trending Reports:
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Biliary Tumor Market: https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/intracranial-stents-market
• Car T Therapy For Acute Lymphoblastic Leukemia All Market: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market
• Cardiac Amyloidosis Market: https://www.delveinsight.com/report-store/al-amyloidosis-market
• Cardiac Restoration Systems Market: https://www.delveinsight.com/report-store/cardiac-restoration-systems-market
• Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-cancer-market
• Chronic Cutaneous Ulcer Market: https://www.delveinsight.com/report-store/chronic-cutaneous-ulcer-market
• Chronic Rhinosinustis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-crswnp-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Continuous Renal Replacement Therapy Machines Market: https://www.delveinsight.com/report-store/continuous-renal-replacement-therapy-machines-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Exocrine Pancreatic Insufficiency Market: https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Gout Market: https://www.delveinsight.com/report-store/gout-market
• Gouty Arthritis Market: https://www.delveinsight.com/report-store/gout-market
• Head And Neck Squamous Cell Carcinoma Market: https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-market
• Healthcare Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market
• Hyperuricemia Market: https://www.delveinsight.com/report-store/hyperuricemia-market
• Implantable Infusion Pumps Market: https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Checkpoint Inhibitors Clinical Trials Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight here
News-ID: 3784233 • Views: …
More Releases from DelveInsight Business Research
Scleroderma Pipeline 2025: Mechanism of Action, Route of Administration, and Cli …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Scleroderma pipeline constitutes 40+ key companies continuously working towards developing 50+ Scleroderma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Scleroderma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Scleroderma Market.
The Scleroderma Pipeline report embraces in-depth…
NK Cell Therapy Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emergi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Nk Cell Therapy pipeline constitutes 140+ key companies continuously working towards developing 160+ Nk Cell Therapy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Nk Cell Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.…
Cough in Idiopathic Pulmonary Pipeline 2025: FDA Approvals, Therapies, Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cough in Idiopathic Pulmonary Fibrosis pipeline constitutes 5+ key companies continuously working towards developing 5+ Cough in Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Cough in Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical…
Cryopyrin-Associated Periodic Syndrome Pipeline 2025: Clinical Trials Overview, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cryopyrin-Associated Periodic Syndrome pipeline constitutes 4+ key companies continuously working towards developing 4+ Cryopyrin-Associated Periodic Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Cryopyrin-Associated Periodic Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.…
More Releases for Checkpoint
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts…
Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitors Market Insights 2019, Global and Chinese Scenario is a professional and indepth study on the current state of the global Immune Checkpoint Inhibitors industry with a focus on the Chinese market. The report provides key statistics on the market status of the Immune Checkpoint Inhibitors manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an…
Global Checkpoint Inhibitors Market 2019 Snapshot Analysis Till 2023
Global Checkpoint Inhibitors Market 2019-2023:
The treatment of cancer patients involves a multidisciplinary approach encompassing surgery, radiotherapy, and chemotherapy. Traditionally, patients with metastatic disease are treated with combination cytotoxic chemotherapy or targeted agents; although chemotherapy treatment has good response rates complete responses are rarely seen. During the last decade the field of immuno-oncology has rapidly advanced and a number of agents which modulate the immune system are beginning to emerge and…
PDF Checkpoint 1.8.5 Improves Color Conversion Handling
Zevrix Solutions announces PDF Checkpoint 1.8.5, a maintenance update to company's PDF preflight and conversion solution. Remarkably fast, PDF Checkpoint automatically preflights, exports as images, splits and optimizes Adobe PDF files. The helps users eliminate costly mistakes and optimize PDF documents for print, web and mobile devices. The new version improves handling of installed ICC profiles which are used to perform conversion of PDF files to different color spaces.
Toronto (ON),…
Global Checkpoint Inhibitors Market Shares and its growth
Global Checkpoint Inhibitors Market was worth USD 6.08 billion in 2016 and is expected to reach USD 21.25 billion by 2021 with a CAGR of 28.4 %.
Checkpoint Inhibitors are drugs used in Immunotherapy. They are generally made up of antibodies that lead an immune system attack on cancer cells. T-cells launches an attack when it detects infected or Cancerous. Immune system uses a series of molecules called checkpoint molecules to…
PDF Checkpoint Now Can Preflight PDF Document Font Names
Toronto (ON), Canada -- Zevrix Solutions today announces PDF Checkpoint 1.7.19, a feature update to the company's PDF preflight and conversion automation tool (http://www.zevrix.com/PDFCheckpoint.php). Remarkably fast, PDF Checkpoint automatically preflights, exports as images, splits and optimizes multiple PDF documents. PDF Checkpoint is an ideal program for users who need a fast, affordable and easy to use solution to check PDF files for errors and prepare them for print, web and…
